Idun Biologics ApS

CVR 43750380 · Private limited company (ApS) · Active · Medium risk

Idun Biologics ApS is a Private limited company (ApS), founded on , based in Aalborg. The company is registered in the industry fremstilling af farmaceutiske præparater. Our model estimates a bankruptcy risk of 1.4% over the next 12 months, which is 1.0 times the average for Danish companies. 3 annual reports have been published, of which 1 more than six months after the end of the financial year. The latest annual report (31 Dec 2025) shows equity of DKK -239k and a net result of DKK -85k. CEO: Jens Frederik Teilfeldt Hansen, Clarisse Eve Chiche-Lapierre.

Bankruptcy risk for Idun Biologics ApS

1.4%
probability of bankruptcy within 12 months
Medium risk

1.0 × the average (1.41%) · higher risk than 75% of active Danish companies

Lowest riskHighest risk

Increases the risk

Negative equityYes · bankruptcy rate 17.5%2.0×
Equity vs. share capital< 0× · bankruptcy rate 17.3%2.0×
Going-concern uncertaintyYes · bankruptcy rate 16.3%1.9×
Equity ratio-50%–0% · bankruptcy rate 14.8%1.7×
Age (years)3–5 yrs · bankruptcy rate 13.3%1.5×
Number of auditors (historical)0 · bankruptcy rate 12.5%1.4×
Published annual reports3–5 · bankruptcy rate 11.7%1.3×
Annual reports filed late1 · bankruptcy rate 11.3%1.3×

Reduces the risk

Current ratio200%–500% · bankruptcy rate 3.4%0.39×
Gross profit growth-10%–0% · bankruptcy rate 4.3%0.49×
Auditor's statementCompilation · bankruptcy rate 5.6%0.64×
Reporting classReporting class B · bankruptcy rate 5.7%0.65×
Number of CEOs2 · bankruptcy rate 5.7%0.65×
Return on assets-20%–0% · bankruptcy rate 6.2%0.70×
RegionNordjylland · bankruptcy rate 6.5%0.74×
Qualification / emphasis of matterNo · bankruptcy rate 7.1%0.80×

The factors show how often companies with the same characteristic went bankrupt compared with the average (“lift”). The risk is a statistical estimate from a model trained on 141,000+ Danish bankruptcies (AUC 0.93) – not a credit rating. Read about the method.

Company details

CVR number
43750380
Status
Active
Company type
Private limited company (ApS)
Founded
(3 years)
Address
Ny Kærvej 37
9000 Aalborg
Municipality
Aalborg
Industry
Fremstilling af farmaceutiske præparater (212000)
Bankruptcies in the industry: Fremstilling af farmaceutiske præparater
Share capital
DKK 40k
Auditor
Deloitte Statsautoriseret Revisionspartnerselskab
Audit opted out
Yes

Warning signs

Annual reports filed late1 of 3
Missing annual reportNo
Negative equityYes
Equity ratio-19.1%
Current ratio461%
Moves (last 2 years)0
CEO changes in total0
CEO's previous bankruptcies0
Other companies at the address1
Going-concern uncertaintyYes

Financials and key figures

Financial year202520242023
Gross profitDKK 475kDKK 517kDKK 662k
Net profitDKK -85kDKK -192kDKK -2,287
EquityDKK -239kDKK -154kDKK 38k
Total assetsDKK 1.3mDKK 834kDKK 117k
CashDKK 76kDKK 139k–
Short-term debtDKK 72kDKK 215k–
Avg. employees11–

Latest annual report: Reporting class B · auditor's statement: Andre erklæringer uden sikkerhed · Deloitte Statsautoriseret Revisionspartnerselskab.

Filed annual reports

Reporting periodPublishedDays after period end
1 Jan 2025 – 31 Dec 2025174
1 Jan 2024 – 31 Dec 2024189 Late
2 Jan 2023 – 31 Dec 2023114

The annual report must reach the Danish Business Authority no later than 5 months after the end of the financial year. We mark reports published more than 6 months after as “late”.

Management, owners and auditor

RoleNameFromTo
CEOJens Frederik Teilfeldt HansenCurrent
CEOClarisse Eve Chiche-LapierreCurrent
Owner (100%)Ymir Holdings ApSCurrent
FounderYmir Holdings ApSCurrent

The CEOs' other companies

Jens Frederik Teilfeldt Hansen – 1 other companies

Clarisse Eve Chiche-Lapierre – 1 other companies

Address history (0 moves)

Ny Kærvej 37, 9000 Aalborg

Other companies at the same address

Similar companies in Aalborg

Questions and answers about Idun Biologics ApS

Has Idun Biologics ApS gone bankrupt?

No, Idun Biologics ApS is not registered as bankrupt in the CVR register. Its status is: active.

What is the bankruptcy risk of Idun Biologics ApS?

Our model estimates a bankruptcy risk of 1.4% over the next 12 months (medium risk), which is 1.0 times the average for Danish companies.

Who is the CEO of Idun Biologics ApS?

Jens Frederik Teilfeldt Hansen, Clarisse Eve Chiche-Lapierre are the CEOs of Idun Biologics ApS.

Who is the auditor of Idun Biologics ApS?

Idun Biologics ApS most recently used Deloitte Statsautoriseret Revisionspartnerselskab.

When was Idun Biologics ApS founded?

Idun Biologics ApS was founded on 2 January 2023.

What is the equity of Idun Biologics ApS?

Equity was DKK -239k according to the annual report for the period ending 31 December 2025.

Source: the CVR register and annual reports published by the Danish Business Authority. The information is updated continuously.